تلفن: ۰۴۱۴۲۲۷۳۷۸۱
تلفن: ۰۹۲۱۶۴۲۶۳۸۴

دانلود رایگان مقاله انگلیسی یک چارچوب مبتنی بر همگرایی برای مقاومت دارویی در برابر سرطان – الزویر ۲۰۱۸

عنوان فارسی: یک چارچوب مبتنی بر همگرایی برای مقاومت دارویی در برابر سرطان
عنوان انگلیسی: A Convergence-Based Framework for Cancer Drug Resistance
تعداد صفحات مقاله انگلیسی : 15 تعداد صفحات ترجمه فارسی : ترجمه نشده
سال انتشار : 2018 نشریه : الزویر - Elsevier
فرمت مقاله انگلیسی : PDF نوع مقاله : ISI
نوع نگارش : مقالات مروری پایگاه : اسکوپوس
کد محصول : E9505 رفرنس : دارد
محتوای فایل : PDF حجم فایل : mb 2
رشته های مرتبط با این مقاله: داروسازی
گرایش های مرتبط با این مقاله: داروشناسی
مجله: سلول سرطانی - Cancer Cell
دانشگاه: Harvard Radiation Oncology Program - Boston - MA - USA
doi یا شناسه دیجیتال: https://doi.org/10.1016/j.ccell.2018.03.025
برای سفارش ترجمه این مقاله با کیفیت عالی و در کوتاه ترین زمان ممکن توسط مترجمین مجرب سایت ایران عرضه؛ روی دکمه سبز رنگ کلیک نمایید.
چکیده

Despite advances in cancer biology and therapeutics, drug resistance remains problematic. Resistance is often multifactorial, heterogeneous, and prone to undersampling. Nonetheless, many individual mechanisms of targeted therapy resistance may coalesce into a smaller number of convergences, including pathway reactivation (downstream re-engagement of original effectors), pathway bypass (recruitment of a parallel pathway converging on the same downstream output), and pathway indifference (development of a cellular state independent of the initial therapeutic target). Similar convergences may also underpin immunotherapy resistance. Such parsimonious, convergence-based frameworks may help explain resistance across tumor types and therapeutic categories and may also suggest strategies to overcome it.

نتیجه گیری

Conclusion

Although the multifactorial and heterogeneous nature of cancer drug resistance remains a significant challenge, systematic experimental and clinical studies across many cancer types have revealed a wealth of resistance mechanisms. This review has proposed a convergence-based framework—pathway reactivation, pathway bypass, and pathway indifference—to organize the multiplicity of individual resistance mechanisms to targeted therapeutics into a parsimonious set of generalizable principles. Importantly, this framework may not prove comprehensive, nor is it intended to be proscriptive. Rather, it seems likely that additional as-yet unsuspected convergences will emerge. Nonetheless, the most fundamental lesson from such consideration may not be the identity of specific resistance convergences themselves, but rather that even highly complex landscapes of resistance can be understood through the paradigm of convergence. Going forward, such frameworks may provide both explanatory power to aid biological understanding and predictive power to guide future therapeutic approaches. Ultimately, these insights may help to achieve durable disease control in patients with advanced cancer.